Medication info
Telmitren ES Tablet 40/5 mg

Telmitren ES Tablet 40/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Jong Kun Dang Co., Ltd.
Appearance
Light yellow oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTPX3)]
Approval status
Active

MFDS item code 202101797 · Approved 2021.02.23 · Insurance code 643308700

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is reached 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Jong Kun Dang Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take Telmisartan and Rosuvastatin at the same time. Telmisartan is effective in treating essential hypertension and reducing the risk of cardiovascular disease, especially in high-risk patients who cannot use ACE inhibitors, reducing the risk of myocardial infarction, stroke, and mortality from cardiovascular disease. Meanwhile, Rosuvastatin is effective in treating hypercholesterolemia and dyslipidemia, particularly when not controlled by diet and exercise. Additionally, Rosuvastatin helps delay the progression of atherosclerosis and reduce the risk of cardiovascular diseases. This combination of medications contributes significantly to improving cardiovascular health in high-risk patients.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is coadministered with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is reached 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication should not be used during pregnancy. It can cause serious harm to the fetus, especially in the early, mid, and late stages of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals who are allergic or hypersensitive to any of the ingredients in this medication should not take it. Women who might become pregnant should use appropriate contraception, and it should not be administered to individuals who are pregnant or breastfeeding. Patients with significantly impaired liver or kidney function or certain liver diseases should consult a physician before using this medication, as its use may be contraindicated depending on the condition. Patients with muscle-related disorders or a history of myalgia or muscle weakness should be cautious while taking this medication, and if muscle pains or weakness become severe, they should consult a healthcare provider immediately. Due to its blood pressure-lowering effect, elderly patients or those with very low blood pressure should be cautious as they may experience dizziness or fainting. Interactions may occur when taking this medication alongside other drugs, so individuals taking other medications should inform their doctor or pharmacist. Particularly, caution is required when combined with certain diuretics, potassium supplements, or other cardiovascular medications. During treatment with this medication, regular tests should be conducted to monitor liver function and blood tests, specifically checking for muscle damage; any abnormal symptoms should be reported to a healthcare provider immediately. In case of overdose, symptoms such as hypotension, dizziness, and worsening kidney function may occur, so the prescribed dosages must be strictly adhered to. Caution is recommended while driving or operating machinery as dizziness or drowsiness may occur. Safety and efficacy in children have not been established, so use is not recommended. This medication contains lactose, so individuals with lactose intolerance should consult a healthcare provider before use. During treatment with this medication, it is advisable to avoid or limit alcohol intake, and special caution is warranted for those with a history of liver disease while undergoing liver function tests.

Side effects

Increased ALT, increased AST, elevated serum creatine phosphokinase (CPK), dizziness, itching, dyspepsia, oral paresthesia, musculoskeletal stiffness, acne, nasopharyngitis, increased serum potassium, glucose in urine, dysuria, rhinitis, discomfort in oropharynx, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, hepatic impairment, increased sweating, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, constipation, nausea, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ophthalmoplegia, headache, facial spasms, paresthesia, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, insufficient effectiveness, cough, palpitations, myalgia, joint pain, fatigue, numbness, paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 degree and 30 degrees Celsius. This will ensure the medication's efficacy is safely preserved.

Appearance and packaging

Appearance

Light yellow oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTPX3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.